Psyence, Revive Therapeutics Ink Private Placements: Capital To Support Drug Trials

Life sciences biotech Psyence Group Inc. PSYGF has closed the second tranche of its previously announced private placement of up to $2.2 million (CA$3 million).

The company issued more than 7.7 million common shares at a unit price of $0.09 (CA$0.12) for gross proceeds of $680.458 (CA$930,223) in addition to the previously announced closing of the first tranche for gross proceeds of almost $90,000 (CA$1.22 million) from a consortium led a member of the Kerzner family.

The non-brokered private placement is subject to the CSE’s approval and securities will be subject to a four-month hold period. The company intends to use the net proceeds to advance its palliative care clinical trial, drug development and for general working capital.

See Also: Psychedelics Company Filament Signs Licensing Deal With Psyence In US, UK And EU

Psyence also announced that executives and officers have agreed to receive more than 1.1 million common shares at a common share price of $0.09 (CA$0.12) in settlement of $104.118 (CA$142,336) in consulting fees and salaries.

As “Insiders,“ and issuance of common shares is considered a “related party" transaction, which exempts the company from the requirements to obtain a formal valuation or minority shareholder approval as it does not exceed 25% of Psyence’s market capitalization.

Meanwhile, Revive Therapeutics Ltd. RVVTF is expanding its private placement to investors residing in Quebec. 

Led by EMD Financial Inc, the offer is being arranged for a minimum of $2.2 million (CA$3 million) and a maximum of 5 million units at $0.11 (CA$0.15) each. Revive, a developer of novel therapeutics for infectious diseases and rare disorders, intends to use the net proceeds for general working capital and clinical development.

Each unit consists of one common share in the company’s capital and one common share purchase warrant, which entitles its holder to acquire one additional common share at a price of $0.15 (CA$0.20) for 36 months from the offering’s closing date.

The units are then offered to purchasers resident in all provinces of Canada including Quebec. Revive may issue up to 33,333,333 units more, for maximum gross proceeds of $3.66 million (CA$5 million) under the listed issuer financing exemption, which makes units offered not subject to resale restrictions pursuant to applicable Canadian securities laws.

Due to the expansion, the offering’s first tranche is anticipated to close on or before Dec. 30, 2022 and any subsequent tranches would close on or before end date Jan. 13, 2023.

Photo courtesy of chrissmith12 and Bru-nO on Pixabay.

Market News and Data brought to you by Benzinga APIs
Posted In: CannabisNewsPenny StocksPsychedelicsFinancingOfferingsManagementMarketsDrug DevelopmentPrivate PlacementPsychedelics Investing
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

The Benzinga Cannabis Capital Conference is coming to Florida

The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.

Get your tickets now on bzcannabis.com – Prices will increase very soon!


Loading...